Stay updated on T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the context of Medical and healthcare-related publications and documentation.
    Difference
    0.3%
    Check dated 2024-06-06T14:32:22.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    16 days ago
    Change Detected
    Summary
    The value 04 09 has been updated to 05 23 on the webpage, indicating a recent change in the study record details related to the T-DM1 and Tucatinib trial for preventing relapses in people with high-risk HER2-Positive Breast Cancer.
    Difference
    0.6%
    Check dated 2024-05-24T03:26:29.000Z thumbnail image
  7. Check
    17 days ago
    Change Detected
    Summary
    The value has been updated from 6 to 7, indicating a recent change in the number of medical and healthcare-related publications or documentation. This update may reflect new information or additional studies being included in the database.
    Difference
    0.3%
    Check dated 2024-05-22T21:04:50.000Z thumbnail image
  8. Check
    39 days ago
    Change Detected
    Difference
    3%
    Check dated 2024-04-30T22:39:38.000Z thumbnail image

Stay in the know with updates to T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the T-DM1 & Tucatinib in HER2+ Breast Cancer Clinical Trial page.